RxDoctor Payments Data

Gregory McIntosh, DO

Urology · Livonia, MINPI 1184688665

Payments from drug & device makers

$8,284in general payments, 2019–2025

Across 311 payments — averaging $26.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$809
  • Johnson & Johnson$778
  • Ferring Pharmaceuticals Inc.$726
  • Pfizer$658
  • AbbVie$562
  • Coloplast$561
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,96796%
  • Education$3174%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,284 in reported general payments places this provider in the 70th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$422,896
Medicare patients
766
Services billed
11,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide46$616,305
ErleadaApalutamide11$153,034
Abiraterone Acetate84$144,715
NubeqaDarolutamide11$143,440
OrgovyxRelugolix45$113,325
MyrbetriqMirabegron146$106,020
GemtesaVibegron107$82,642
Tamsulosin Hcl1,564$30,009
Mirabegron ErMirabegron36$18,641
Finasteride883$16,417
Acyclovir20$8,064
Tolterodine Tartrate111$6,558
Testosterone69$4,596
Solifenacin Succinate79$4,358
NitrofurantoinNitrofurantoin Macrocrystal186$3,280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$809$722,326192 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$537$195,967152 claims
Johnson & JohnsonErleada$778$153,03411 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$121$144,71584 claims
BayerNubeqa$113$143,44011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 urology providers in Michigan.

Other urology in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →